Alnylam Pharmaceuticals received a milestone payment from its partner Roche for the initiation of pre-IND studies for an RNAi therapeutics product candidate. Financial terms of were not disclosed. “We are excited by the progress our partner Roche is making in developing their own portfolio of RNAi therapeutics based on Alnylam technology and intellectual property,” said Barry Greene, president and chief operating officer of Alnylam. “Since the start of our collaboration with Roche in 2007, we...